Sanofi-Aventis Signs MOU With Korean Health Ministry To Invest $55 Million In R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
The current blockbuster-era led by the U.S. is being replaced by an era of specific products developed and made for specific regions, races or countries, Sanofi official says.
You may also be interested in...
Pfizer Korea Signs Development Pact With State KRIBB For Liver and Gastric Cancer Drugs
SEOUL - Two years after signing a memorandum of understanding on cooperation, Pfizer and Korea's state-run Korea Research Institute for Bioscience and Biotechnology signed a more formal agreement May 18 to start collaborative research work for joint development of drugs for liver and gastric cancer
Kyowa Hakko’s Parkinson’s Drug Is Not Approvable – U.S. FDA
Kyowa Hakko will work with U.S. FDA to determine a path forward for its Parkinson's treatment istradefylline (KW-6002) after receiving a "not approvable" letter from the agency Feb. 25, the Tokyo-based firm said Feb. 27
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.